JP2008528510A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528510A5 JP2008528510A5 JP2007552335A JP2007552335A JP2008528510A5 JP 2008528510 A5 JP2008528510 A5 JP 2008528510A5 JP 2007552335 A JP2007552335 A JP 2007552335A JP 2007552335 A JP2007552335 A JP 2007552335A JP 2008528510 A5 JP2008528510 A5 JP 2008528510A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight gain
- administration
- activating compound
- flush
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000004584 weight gain Effects 0.000 claims 9
- 235000019786 weight gain Nutrition 0.000 claims 9
- 230000003213 activating effect Effects 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 102000011990 Sirtuin Human genes 0.000 claims 5
- 108050002485 Sirtuin Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 4
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims 4
- RNTJDJDUXWVMJY-UHFFFAOYSA-N CC(C)(OC(=O)C(=O)c1ccc(O)cc1)C1Cc2cc3ccc(=O)oc3cc2O1 Chemical compound CC(C)(OC(=O)C(=O)c1ccc(O)cc1)C1Cc2cc3ccc(=O)oc3cc2O1 RNTJDJDUXWVMJY-UHFFFAOYSA-N 0.000 claims 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
- 235000011990 fisetin Nutrition 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims 2
- 229960001285 quercetin Drugs 0.000 claims 2
- 235000005875 quercetin Nutrition 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 230000002427 irreversible effect Effects 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
Claims (20)
- サーチュイン活性化化合物を含む、薬物誘発性体重増加を処置または予防する必要がある被験体において薬物誘発性体重増加を処置または予防するための組成物。
- 前記体重増加が糖尿病処置薬の投与と関連している、請求項１に記載の組成物。
- 前記糖尿病処置薬が、スルホニル尿素、チアゾリジンジオン、メグリチナイド、ナテグリニド、レパグリニドまたはインスリンのうちの少なくとも１種類である、請求項２に記載の組成物。
- 前記体重増加が抗鬱薬の投与と関連している、請求項１に記載の組成物。
- 前記抗鬱薬が、三環系抗鬱薬、不可逆的モノアミンオキシダーゼ阻害剤（ＭＡＯＩ）、選択的セロトニン再取り込み阻害剤（ＳＳＲＩ）、ブプロピオン、パロキセチンまたはミルタザピンのうちの少なくとも１種類である、請求項４に記載の組成物。
- 前記体重増加がステロイドまたはホルモンの投与と関連している、請求項１に記載の組成物。
- 前記体重増加がβ遮断薬の投与と関連している、請求項１に記載の組成物。
- 前記体重増加がα遮断薬の投与と関連している、請求項１に記載の組成物。
- 前記体重増加が避妊薬の投与と関連している、請求項１に記載の組成物。
- 前記サーチュイン活性化化合物が、式１〜２５、３０、３２〜６５および６９〜７６からなる群より選択される式を含む、請求項１に記載の組成物。
- 前記サーチュイン活性化化合物が、レスベラトロール、フィセチン、ブテイン、ピセアタンノールまたはケルセチンである、請求項１に記載の組成物。
- 前記被験体がヒトである、請求項１に記載の組成物。
- 少なくとも１種類のサーチュイン活性化化合物および少なくとも１種類の体重増加を誘発する薬物を含む組成物。
- サーチュイン活性化化合物を含む、紅潮を処置または予防する必要がある被験体において紅潮を処置または予防するための組成物。
- 前記紅潮が薬物誘発性紅潮である、請求項１４に記載の組成物。
- 前記紅潮が化学療法薬の投与と関連している、請求項１５に記載の組成物。
- 前記紅潮がニコチン酸の投与と関連している、請求項１５に記載の組成物。
- 前記サーチュイン活性化化合物が、式１〜２５、３０、３２〜６５および６９〜７６からなる群より選択される式を含む、請求項１４に記載の組成物。
- 前記サーチュイン活性化化合物が、レスベラトロール、フィセチン、ブテイン、ピセアタンノールまたはケルセチンである、請求項１４に記載の組成物。
- 前記被験体がヒトである、請求項１４に記載の組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64591605P | 2005-01-20 | 2005-01-20 | |
| US64596205P | 2005-01-21 | 2005-01-21 | |
| PCT/US2006/002267 WO2006079021A2 (en) | 2005-01-20 | 2006-01-20 | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528510A JP2008528510A (ja) | 2008-07-31 |
| JP2008528510A5 true JP2008528510A5 (ja) | 2009-01-29 |
Family
ID=36578920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007552335A Withdrawn JP2008528510A (ja) | 2005-01-20 | 2006-01-20 | 紅潮および／または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060276416A1 (ja) |
| EP (1) | EP1841415A2 (ja) |
| JP (1) | JP2008528510A (ja) |
| AU (1) | AU2006206274A1 (ja) |
| CA (1) | CA2595486A1 (ja) |
| WO (1) | WO2006079021A2 (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090169585A1 (en) * | 2003-10-23 | 2009-07-02 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity |
| US20050158376A1 (en) * | 2003-10-23 | 2005-07-21 | Sardi William F. | Dietary supplement and method of processing same |
| EP1708689A2 (en) * | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| EP1753708B1 (en) * | 2004-01-20 | 2018-02-21 | Brigham Young University | Novel sirtuin activating compounds and methods for making the same |
| CN1964627B (zh) * | 2004-06-04 | 2011-10-19 | 华盛顿大学 | 治疗神经病变的方法和组合物 |
| ZA200701232B (en) | 2004-07-15 | 2008-08-27 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ， インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
| US20090215681A1 (en) * | 2005-02-15 | 2009-08-27 | Joslin Diabetes Center | Methods of Diagnosis and Treatment of Metabolic Disorders |
| US20090142335A1 (en) * | 2005-02-15 | 2009-06-04 | Joslin Diabetes Center | Methods of diagnosis and treatment of metabolic disorders |
| US20060229265A1 (en) * | 2005-03-30 | 2006-10-12 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
| US8524734B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US20060292099A1 (en) * | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| WO2006138418A2 (en) | 2005-06-14 | 2006-12-28 | President And Fellows Of Harvard College | Improvement of cognitive performance with sirtuin activators |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| CN101176786A (zh) * | 2006-11-08 | 2008-05-14 | 中国科学院上海生命科学研究院 | 增加胰岛素敏感性的方法和组合物 |
| WO2008060400A2 (en) * | 2006-11-15 | 2008-05-22 | Sirtris Pharmaceuticals, Inc. | Sirtuin polymorphisms and methods of use thereof |
| US8431552B2 (en) * | 2007-01-16 | 2013-04-30 | Chien-Hung Chen | Composition for treating metabolic syndrome |
| US20100210692A1 (en) * | 2007-03-28 | 2010-08-19 | Farmer Stephen R | Methods of treatment using sirt modulators and compositions containing sirt1 modulators |
| US8404275B2 (en) | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| JP2010532358A (ja) * | 2007-07-01 | 2010-10-07 | ピーター ハバウシ，ジョセフ | 咀嚼可能外層を有する配合剤 |
| EP2018861A1 (en) * | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| US9339500B2 (en) * | 2008-03-04 | 2016-05-17 | Intra-Cellular Therapies, Inc. | Methods of treating vasomotor symptoms |
| AU2009248057B2 (en) * | 2008-05-13 | 2013-02-21 | Genmedica Therapeutics Sl | Salicylate conjugates useful for treating metabolic disorders |
| CA2666036C (en) * | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
| CA2726588C (en) | 2008-06-03 | 2019-04-16 | Karl Kossen | Compounds and methods for treating inflammatory and fibrotic disorders |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010011836A2 (en) * | 2008-07-25 | 2010-01-28 | Emory University | Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| CA2739893C (en) | 2008-10-07 | 2016-10-04 | Mpex Pharmaceuticals, Inc. | Inhalation of levofloxacin for reducing lung inflammation |
| KR20110091510A (ko) | 2008-10-07 | 2011-08-11 | 엠펙스 파마슈티컬즈, 인코포레이티드 | 약동학 개선을 위한 에어로졸 플루오로퀴놀론 제형 |
| AU2010224866C1 (en) * | 2009-03-16 | 2015-01-15 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
| US20100239552A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Combination Therapies for Treating Metabolic Disorders |
| WO2010107702A1 (en) * | 2009-03-16 | 2010-09-23 | Ipintl, Llc | Treating alzheimer's disease and osteoporosis and reducing aging |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| WO2010132437A1 (en) | 2009-05-12 | 2010-11-18 | Albany Molecular Research, Inc. | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof |
| CA2760837C (en) * | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| WO2011002673A1 (en) * | 2009-07-01 | 2011-01-06 | Temple University - Of The Commonwealth System Of Higher Education | Leptin agonist and methods of use |
| AU2010289397B2 (en) | 2009-09-03 | 2016-05-26 | Bioenergenix | Heterocyclic compounds for the inhibition of PASK |
| RU2015130524A (ru) | 2009-09-04 | 2018-12-21 | Раптор Фармасьютикалз Инк. | Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза |
| FI20106119A0 (fi) * | 2010-10-27 | 2010-10-27 | Sirtuin Valley Oy | Energia-aineenvaihduntaan vaikuttava koostumus |
| US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
| WO2012094462A2 (en) | 2011-01-05 | 2012-07-12 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| US8916561B2 (en) | 2011-03-02 | 2014-12-23 | Bioenergenix, Llc | Substituted quinoxaline compounds for the inhibition of PASK |
| CA2828349C (en) | 2011-03-02 | 2019-05-21 | John M. Mccall | Heterocyclic compounds for the inhibition of pask |
| WO2012141876A1 (en) * | 2011-04-15 | 2012-10-18 | Nestec S.A. | Methods for regulating sirtuin gene expression |
| JP2012236793A (ja) * | 2011-05-11 | 2012-12-06 | Kikkoman Corp | Ａｍｐｋ活性化剤 |
| JP6158801B2 (ja) | 2011-07-15 | 2017-07-05 | ニューサート サイエンシーズ， インコーポレイテッド | 代謝経路を変調させるための組成物および方法 |
| CN104105478A (zh) | 2011-10-28 | 2014-10-15 | 维塔利斯公司 | 抗发红组合物 |
| US8916528B2 (en) | 2011-11-16 | 2014-12-23 | Resveratrol Partners, Llc | Compositions containing resveratrol and nucleotides |
| EP2799081A4 (en) * | 2011-12-27 | 2015-06-24 | Tokiwa Phytochemical Co Ltd | SIRTUIN ACTIVATOR |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| TWI485145B (zh) | 2012-10-26 | 2015-05-21 | Ind Tech Res Inst | Ｐ型有機半導體材料與光電元件 |
| CN108452311A (zh) | 2012-11-13 | 2018-08-28 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
| AU2014236687A1 (en) * | 2013-03-15 | 2015-09-10 | Nusirt Sciences, Inc. | Leucine and nicotinic acid reduces lipid levels |
| EP2801357A1 (en) | 2013-05-10 | 2014-11-12 | IMD Natural Solutions GmbH | Carboxylated stilbenes for activating AMPK and sirtuins |
| WO2015153683A1 (en) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Anti-fibrotic pyridinones |
| KR20170117170A (ko) | 2015-02-19 | 2017-10-20 | 퍼듀 퍼머 엘피 | 위 배출을 감소시키기 위한 방법 및 조성물 |
| CN105153090A (zh) * | 2015-07-17 | 2015-12-16 | 浙江海洋学院 | 4′-溴-7-异戊烯氧基-2,3-二氢黄酮和制备方法以及在制备抗抑郁药物中的应用 |
| CN105380955A (zh) * | 2015-09-24 | 2016-03-09 | 成都普瑞法科技开发有限公司 | 土大黄苷在治疗溃疡性结肠炎药物中的应用 |
| US20180169085A1 (en) * | 2016-12-19 | 2018-06-21 | Augusta University Reserch Institute, Inc. | Combination Therapy for Hemorrhagic Injury |
| US11254700B2 (en) | 2017-12-01 | 2022-02-22 | University Of Hawaii | GSK-3β inhibitors and use thereof in methods of treatment |
| IT201900003325A1 (it) * | 2019-03-07 | 2020-09-07 | C I A M S R L | Composizione per la prevenzione e trattamento della dermatite atopica |
| WO2021096882A1 (en) * | 2019-11-11 | 2021-05-20 | Nusirt Sciences, Inc. | Compositions, methods and kits for altering adipocytes |
| AU2022367432A1 (en) | 2021-10-14 | 2024-05-02 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| EP1027045A4 (en) * | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY |
| US6448450B1 (en) * | 1998-05-08 | 2002-09-10 | Calyx Therapeutics, Inc. | 1-(3,5-dimethoxyphenyl)-2-(4-hydroxyphenyl)-ethylene for diabetes treatment |
| US6331633B1 (en) * | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
| US7452664B2 (en) * | 1999-12-15 | 2008-11-18 | Massachusetts Institute Of Technology | Methods for identifying agents which alter histone protein acetylation |
| WO2001070212A2 (en) * | 2000-03-23 | 2001-09-27 | Interhealth Nutraceuticals Incorporated | Method and composition for preventing or reducing the symptoms of menopause |
| US6475530B1 (en) * | 2000-05-31 | 2002-11-05 | Eric H. Kuhrts | Methods and compositions for producing weight loss |
| US6552085B2 (en) * | 2000-08-16 | 2003-04-22 | Insmed Incorporated | Compositions containing hypoglycemically active stilbenoids |
| KR100407399B1 (ko) * | 2000-08-22 | 2003-11-28 | 주식회사 뉴로넥스 | 세로토닌 ｎ-아세틸트란스퍼라제의 활성 억제제 |
| IT1320080B1 (it) * | 2000-10-25 | 2003-11-18 | Giuliani Spa | Composizione per uso farmaceutico o dietetico. |
| EP1343502A2 (en) * | 2000-11-17 | 2003-09-17 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
| BR0204228A (pt) * | 2001-02-20 | 2004-06-22 | Randy Ziegler | Métodos para melhorar os sintomas de uma psicose e de esquizofrenia e para triar moléculas de teste, e, composto orgânico |
| GB0123991D0 (en) * | 2001-10-05 | 2001-11-28 | Arachnova Ltd | New therapeutic use |
| US20070092551A1 (en) * | 2003-05-02 | 2007-04-26 | Takara Bio Inc. | Therapeutic agent |
| JP2006528700A (ja) * | 2003-05-20 | 2006-12-21 | エリモス・ファーマスーティカルズ・エルエルシー | 肥満の治療のためのカテコールブタンの投与のための方法と組成物 |
| CA2529510A1 (en) * | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Compositions for manipulating the lifespan and stress response of cells and organisms |
| US20050136429A1 (en) * | 2003-07-03 | 2005-06-23 | Massachusetts Institute Of Technology | SIRT1 modulation of adipogenesis and adipose function |
| EP1708689A2 (en) * | 2003-12-29 | 2006-10-11 | The President and Fellows of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
| US7838503B2 (en) * | 2005-06-15 | 2010-11-23 | Children's Medical Center Corporation | Methods for extending the replicative lifespan of cells |
-
2006
- 2006-01-20 CA CA002595486A patent/CA2595486A1/en not_active Abandoned
- 2006-01-20 EP EP06719216A patent/EP1841415A2/en not_active Withdrawn
- 2006-01-20 JP JP2007552335A patent/JP2008528510A/ja not_active Withdrawn
- 2006-01-20 WO PCT/US2006/002267 patent/WO2006079021A2/en active Application Filing
- 2006-01-20 AU AU2006206274A patent/AU2006206274A1/en not_active Abandoned
- 2006-01-20 US US11/336,258 patent/US20060276416A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528510A5 (ja) | ||
| KR101900989B1 (ko) | 정신분열증 치료에서의 4-((1r,3s)-6-클로로-3-페닐-인단-1-일)-1,2,2-트리메틸-피페라진 및 그 염의 투여 방법 | |
| Alam et al. | Therapeutic effectiveness and safety of repurposing drugs for the treatment of COVID-19: position standing in 2021 | |
| HRP20200828T1 (hr) | Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe | |
| JP2019052154A5 (ja) | ||
| WO2021147235A1 (zh) | 法匹拉韦在治疗冠状病毒感染方面的应用 | |
| Moreira | The efficacy and tolerability of bupropion in the treatment of major depressive disorder | |
| JP2008536946A (ja) | うつ病の処置または予防のための新規の治療的組み合わせ | |
| US20180000768A1 (en) | Intestinal fxr agonism enhances glp-1 signaling to restore pancreatic beta cell functions | |
| BRPI0818687A2 (pt) | composto espiro, o sal deste farmaceuticamente aceitavél ou o solvato deste, composição farmacêutica, medicamento agonista de gpr40, agente promotor da secreção de insulina ou um agente hipoglicêmico, uso do composto espíro, o sal deste farmaceuticamente aceitavél ou o solvato deste, e, métodos para a ativação de gpr40, para promover secreção de insulina ou diminuir o nível de glicose sanguínea, e para tratar ou prevenir uma doença. | |
| JP2013544850A5 (ja) | ||
| AR075424A1 (es) | Composicion farmaceutica que comprende un inhibidor de sglt2, metodos de tratamiento y sus usos | |
| BRPI0711872A2 (pt) | tratamento para distúrbios depressivos | |
| CO6251239A2 (es) | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo junto con un inhibidor de dpp iv | |
| NO20065880L (no) | 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor | |
| BRPI0712039A2 (pt) | uso de flibanserina para o tratamento de distúrbios de desejo sexual pós-menopausa | |
| CN102316863B (zh) | 5-苄基氨基水杨酸衍生物或其盐的医药用途 | |
| JP2011512347A5 (ja) | ||
| DeBattista et al. | Utility of atypical antipsychotics in the treatment of resistant unipolar depression | |
| Yoshino et al. | Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex | |
| NO20091644L (no) | Hurtig desintegrerende, lyofiliserte orale formuleringer av en trombinreseptorantagonist | |
| Yoshino et al. | Oseltamivir (Tamiflu®) increases dopamine levels in the rat medial prefrontal cortex | |
| CN101500567B (zh) | P38激酶抑制剂治疗精神障碍的用途 | |
| JP2009542820A5 (ja) | ||
| US20040229942A1 (en) | Analeptic and antidepressant combinations |